Fate Therapeutics
FATE
170 hedge funds and large institutions have $203M invested in Fate Therapeutics in 2023 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 59 increasing their positions, 55 reducing their positions, and 36 closing their positions.
7% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 55
10% less funds holding
Funds holding: 188 → 170 (-18)
14.06% less ownership
Funds ownership: 110.94% → 96.88% (-14%)
44% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 36
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
61% less capital invested
Capital invested by funds: $520M → $203M (-$317M)
87% less call options, than puts
Call options by funds: $4K | Put options by funds: $31K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$4.77M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$4.1M |
| 3 |
MAM
Monaco Asset Management
Monaco
|
+$2.79M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.69M |
| 5 |
BlackRock
New York
|
+$1.68M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$26.6M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$7.96M |
| 3 |
Rafferty Asset Management
New York
|
-$4.55M |
| 4 |
Voloridge Investment Management
Jupiter,
Florida
|
-$3.97M |
| 5 |
Citigroup
New York
|
-$3.53M |
FATE Hedge Fund Activity: Q3 2023 in Review
170 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Fate Therapeutics (FATE) for Q3 2023, worth a combined $203M — down 61% from $520M a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of FATE and 20 opened new positions — a net loss of 16 holders — while 55 trimmed existing stakes and 59 added.
The largest buyer was Millennium Management, adding an estimated $4.77M. The largest seller was State Street, cutting an estimated $26.6M.
- 170 institutional investors held Fate Therapeutics (FATE) as of Q3 2023, down from 188 in Q2 2023.
- Funds reported $203M of Fate Therapeutics stock for Q3 2023, down 61% quarter-over-quarter.
- 20 funds opened new Fate Therapeutics positions in Q3 2023 and 36 closed out, a net change of -16 holders.
- The largest Fate Therapeutics buyer in Q3 2023 was Millennium Management, an estimated $4.77M added.
- The largest Fate Therapeutics seller in Q3 2023 was State Street, an estimated $26.6M sold.
Based on aggregated 13F filings for Q3 2023.